Browse > Article

Change of absolute neutrophil count after intravenous immunoglobulin administration for the children with idiopathic thrombocytopenic purpura  

Shin, Hyun Jung (Department of Pediatrics Keimyung University School of Medicine)
Bang, In Kug (Department of Pediatrics Keimyung University School of Medicine)
Choe, Byung Kyu (Department of Pediatrics Keimyung University School of Medicine)
Hwang, Jin-Bok (Department of Pediatrics Keimyung University School of Medicine)
Kim, Jun Sik (Department of Pediatrics Keimyung University School of Medicine)
Kim, Heung Sik (Department of Pediatrics Keimyung University School of Medicine)
Publication Information
Clinical and Experimental Pediatrics / v.50, no.10, 2007 , pp. 982-986 More about this Journal
Abstract
Purpose : Intravenous immunoglobulin (IVIG) is effective for the treatment of idiopathic thrombocytopenic purpura (ITP) in children. Recently, several reports have been published that show its impact on the absolute neutrophil count. The present study was performed to confirm these findings. Methods : Data on 26 ITP patients were analyzed. Patients with febrile illness or increased C-reactive protein levels at presentation, which would influence the neutrophil counts, were excluded to determine the sole impact of IVIG. In addition, patients who received steroid treatment were also excluded. Results : Sixteen boys and ten girls were analyzed. For patients who received an IVIG dose of 0.4 g/kg/day (n=17), the absolute neutrophil count (ANC) measured next day was significantly decreased. For patients who received an IVIG dose of 1 g/kg/day (n=9), the ANC measured the next day was also significantly decreased. However, the decrease was more profound in the high-dose group compared to the low-dose group. Among six cases with profoundly decreased ANC greater than $1,000/mm^3$, four patients (67%) received IVIG at a dose of 1 g/kg/day. All four cases with increased ANC were treated with IVIG dose of 0.4 g/kg/day, and three cases (75%) among them had a febrile reaction during IVIG administration. None of the cases with decreased ANC had a febrile reaction. No cases had infectious complications reported. Conclusion : IVIG treatment for ITP patients appears to suppress the ANC. This decrease of ANC was more pronounced when a higher dose of IVIG was used. Some cases with increased ANC counts after IVIG use were found only in low-dose IVIG group, and was associated with febrile reactions during IVIG use.
Keywords
Idiopathic thrombocytopenic purpura; Absolute neutrophil count; Intravenous immunoglobulin;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Berkovitch M, Dolinski G, Tauber T, Aladjem M, Kaplinsky C. Neutropenia as a complication of intravenous immunoglobulin(IVIG) therapy in children with immune thrombocytopenic purpura: common and non-alarming. Int J Immunopharmacol 1999;21:411-5   DOI   ScienceOn
2 Niebanck AE, Kwiatkowski JL, Raffini LJ. Neutropenia following IVIG therapy in pediatric patients with immunemediated thrombocytopenia. J Pediatr Hematol Oncol 2005; 27:145-7   DOI   ScienceOn
3 Beck CE, Nathan PC, Parkin PC, Blanchette VS, Macarthur C. Corticosteroids versus intravenous immune globulin for the treatment of acute immune thrombocytopenic purpura in children: a systematic review and meta-analysis of randomized controlled trials. J Pediatr 2005;147:521-7   DOI   ScienceOn
4 Tam DA, Morton LD, Stroncek DF, Leshner RT. Neutropenia in a patient receiving intravenous immune globulin. J Neuroimmunol 1996;64:175-8   DOI   ScienceOn
5 Tsujimoto H, Takeshita S, Nakatani K, Kawamura Y, Tokutomi T, Sekine I. Intravenous immunoglobulin therapy induces neutrophil apoptosis in Kawasaki disease. Clin Immunol 2002;103:161-8   DOI   ScienceOn
6 Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002;346:995-1008   DOI   ScienceOn
7 Sugita K, Eguchi M. Suppressive effect of intravenous immunoglobulin on peripheral blood neutrophil count in patients with idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 2005;27:7-10   DOI   ScienceOn
8 Watts RG. Idiopathic thrombocytopenic purpura: a 10-year natural history study at the Childrens Hospital of Alabama. Clin Pediatr(Phila) 2004;43:691-702   DOI
9 Schiavotto C, Ruggeri M, Rodeghiero F. Adverse reactions after high-dose intravenous immunoglobulin: incidence in 83 patients treated for idiopathic thrombocytopenic purpura (ITP) and review of the literature. Haematologica 1993;78: 35-40
10 Tarantino MD, Young G, Bertolone SJ, Kalinyak KA, Shafer FE, Kulkarni R, et al. Single dose of anti-D immune globulin at 75 microg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diag nosed immune thrombocytopenic purpura in children. J Pediatr 2006;148:489-94   DOI   ScienceOn
11 Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol 2005;29:173-84   DOI   ScienceOn
12 Nugent DJ. Immune thrombocytopenic purpura of childhood. Hematology Am Soc Hematol Educ Program 2006:97-103
13 Bolton-Maggs P. Severe bleeding in idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 2003;25(Suppl 1): S47-51   DOI   ScienceOn
14 Treutiger I, Rajantie J, Zeller B, Henter JI, Elinder G, Rosthoj S. Does treatment of newly diagnosed idiopathic thrombocytopenic purpura reduce morbidity? Arch Dis Child 2007;92:704 -7   DOI   ScienceOn
15 Tarantino MD, Madden RM, Fennewald DL, Patel CC, Bertolone SJ. Treatment of childhood acute immune thrombocytopenic purpura with anti-D immune globulin or pooled immune globulin. J Pediatr 1999;134:21-6   DOI   ScienceOn
16 Teeling JL, De Groot ER, Eerenberg AJ, Bleeker WK, Van Mierlo G, Aarden LA, et al. Human intravenous irnmuno globulin(IVIG) preparations degranulate human neutrophils in vitro. Clin Exp Immunol 1998;114:264-70   DOI
17 Altznauer F, von Gunten S, Spath P, Simon HU Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations. J Allergy Clin Immunol 2003;112:1185-90   DOI   ScienceOn
18 Benesch M, Kerbl R, Lackner H, Berghold A, Schwinger W, Triebl-Roth K, et al. Low-dose versus high-dose immunoglobulin for primary treatment of acute immune thrombocytopenic purpura in children: results of a prospective, randomized single-center trial. J Pediatr Hematol Oncol 2003;25:797 -800   DOI   ScienceOn
19 Bolton-Maggs PH. Idiopathic thrombocytopenic purpura. Arch Dis Child 2000;83:220-2   DOI
20 Kuhne T, Buchanan GR, Zimmerman S, Michaels LA, Kohan R, Berchtold W, et al. A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpuratl (ITP) from the Intercontinental Childhood ITP Study Group. J Pediatr 2003;143: 605-8   DOI   ScienceOn
21 Blanchette V, Carcao M. Intravenous immunoglobulin G and anti-D as therapeutic interventions in immune thrombocytopenic purpura. Transfus Sci 1998;19:279-88   DOI   ScienceOn
22 Lee JH, Lee KS. Efficacy of very low-dose(200 mg/kg /d) with short-term intravenous immunoglobulin G therapy according to individual response of acute immune thrombocytopenic purpura in childhood. Clin Pediatr Hematol Oncol 2006;13:143-9
23 Park JA, Park SS, Lim YT. Neutropenia following IVIG treatment in children with idiopathic thrombocytopenic purpura. In: Program & Abstract, the 56th Annual Fall Meeting of the Korean Pediatric Society; 2006. p. 113
24 Imbach P, Barandun S, d' Apuzzo V, Baumgartner C, Hirt A, Morell A, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981;1:1228-31